Searched for
WOCKHARDT FINANCIAL RESULTS
Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Smallcap winners! Wockhardt, Tata Tech, CAMS, other stocks rally up to 11% despite overall market weaknessSmallcap stocks outperformed on Tuesday despite weak broader markets, with Wockhardt, Tata Tech and CAMS gaining up to 11% on strong Q4 ear...
- Wockhardt shares jump 9% after strong Q4 turnaround, robust FY26 growthWockhardt shares saw a significant jump on Tuesday. The pharmaceutical company reported a strong turnaround in its March quarter performanc...
- Wockhardt Q2 Results: Co swings to profit at Rs 82 croreDrug firm Wockhardt on Monday reported a consolidated profit after tax of Rs 82 crore for the second quarter ended September 30, 2025.
- Wockhardt ties up with various partners to roll out products in US market"The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing pr...
- Early US probe findings may impact pharma companiesUnder the Sherman Anti-trust Act, a maximum penalty of $100 million could be imposed.
- Wockhardt to receive Rs 1280 crore from Danone on sale of nutrition brands like Dexolac and FarexTroubled pharmaceutical major is set to received Rs 1,280 crore from French dairy giant Danone from sale of nutrition brands like Dexolac a...
- Wockhardt: Will investors forgive the company?Forget its financial and legal woes, Habil Khorakiwala wants the world to notice that Wockhardt is on the road to recovery.
- Investors unwilling to forgive Wockhardt, promoter for failingsForget its financial and legal woes, Habil Khorakiwala wants the world to notice that Wockhardt is on the road to recovery.
- Pfizer keen to buy Wockhardt's biotech businessThe American company has just completed the $68-billion acquisition of biotech major Wyeth, which is a new drug developer.
- Wockhardt in talks with MNCs for biosimilar JVWockhardt is in talks with a clutch of multinational pharma companies, including Eli Lilly, Roche, Sandoz, Pfizer and Sanofi-Aventis, to fi...
- Banks may buy FCCBs of WockhardtIndian banks are likely to buy Wockhardt's FCCBs from foreign investors, as part of the drug major’s corporate debt restructuring (CDR) pro...
- Another French co Vetoquinol in race for Wockhardt’s vet unitFrench company Vetoquinol is the latest in a string of global majors looking to acquire the Rs 250-crore veterinary business of Wockhardt P...
- Wockhardt gets Rs 100-cr SBI lifelineState Bank of India, the country’s largest bank, has sanctioned a Rs 100 crore lifeline loan to financially troubled pharma major Wockhardt...
- Khorakiwala quits as MD amid Wockhardt debt pileMumbai-based pharma major Wockhardt on Tuesday announced a major organisational change and admitted that it was facing problems in servicin...
- Pricing pressure in Europe, interest costs remain a worry for WockhardtWockhardt, India’s seventh-largest pharma company by revenues, has lately been facing investor concern on account of high interest costs, F...
- Investors prefer to sit on cash than invest in IPOsThe persistent fall in the secondary market has affected the primary market badly.
- Corporate events this weekCheck out corporate events this week.
- State FDA pulls plug on Wockhardt insulin drugThe state Food and Drug Administration (FDA) has ordered Wockhardt to withdraw its diabetic drug Wosulin from the state.
Load More
